Archives

This is a feasibility study which has a Longitudinal Cohort design, following up participants at selected time points over a 1 year duration. The study will recruit 2 distinct groups: (1) patients with symptoms of cognitive impairment, and (2) study partners who are cognitively normal. The patients recruited to group 1 will have been recently referred to a Memory Assessment Service by their GP with suspected Mild Cognitive Impairment (MCI) & mild dementia. All patients referred to a Memory Assessment Service for this reason will be potentially eligible for inclusion in the study. Close friends or family members involved in looking after the cognitively impaired participants will also be asked to participate as study partners to attempt to measure the impact that looking after a partner, friend or family member with memory problems can have on a carer’s Quality of Life and other variables such as financial burden. Both cognitively impaired participants and their study partners will be given the option of additionally participating in two sub-studies:

– Mobile data collection: Using a web/mobile app to collect self-reported data on a more regular basis from home

– Wearable device: Using a wearable device that looks like a watch to collect information on activity and sleep

For the Esprit study, 1863 non-institutionalized persons aged 65 years and over were randomly recruited in 1999 from the Montpellier district electoral rolls, and re-examined 6-times at 2-3 yearly intervals. Objectives:

1) To determine current and lifetime prevalence as well as incidence of psychiatric disorder in the elderly;
2) to determine the risk factors for these disorders, their relative weight and interactions;
3) to study clinical heterogeneity;
4) to estimate the probability of transition towards a subsyndromic state or a given pathology;
5) to elaborate predictive etiological models.

The purpose of this project is to describe changes in health and functioning among older people. Living conditions and life-style are studied as predictors of health, functioning, need of care and mortality. This multidisciplinary study includes several prospective arms. In 1988 a random sample of people aged 65-84 years were interviewed in their homes. Follow up interviews for them were conducted in 1996 and 2004. During the same years 65-69 year old people were interviewed to capture cohort changes in aging. In 1989 all men born before 1924 and every other woman living in nursing home were interviewed. In 1989 all 75-year-old and 1990 all 80-year-old residents of Jyväskylä were studied in the laboratory with extensive functional testing and clinical examinations. The 75-year-old people were followed up after 5, 10 and 15 years and the 80-year-olds after 5 and 10 years. In addition, register-based data on hospital and long-term care is being updated until the entire cohort becomes extinct. Altogether, 2500 have participated in these studies.

The main objective of the FINGER study is to find out if a multi-domain intervention could prevent cognitive decline among older people. With this intervention we also aim to investigate the effect of the multidomain intervention on disability, quality of life, depressive symptoms, the use of health care services and vascular risk factors.

Participants of the FINGER study have previously taken part in population-based non-intervention studies. They have an increased risk of cognitive decline. At the beginning of the study they are 60-77 years old. The FINGER study enrols approximately 1200 participants in six centers in Finland: Helsinki, Kuopio, Oulu, Seinäjoki, Turku and Vantaa.

The Health Survey for England series was designed to monitor trends in the nation’s health, to estimate the proportion of people in England who have specified health conditions, and to estimate the prevalence of risk factors associated with these conditions. The surveys provide regular information that cannot be obtained from other sources on a range of aspects concerning the public’s health. The surveys have been carried out since 1994 by the Joint Health Surveys Unit of NatCen Social Research and the Research Department of Epidemiology and Public Health at UCL. Individuals are asked for written consent to link their HSE records to mortality and cancer registration data (from HSE 1994 onwards) and to Hospital Episodes Statistics (from HSE 2003 participants onwards).

Each survey in the series includes core questions and measurements (such as blood pressure, height and weight, and analysis of blood and saliva samples), as well as modules of questions on topics that vary from year to year. New topics in 2014 year included hearing and mental health. The achieved sample for the 2014 survey was 8,077 adults (aged 16 and over) and 2,003 children (aged 0-15).

i-Share (Internet-based Students HeAlth Research Enterprise) is a new open and prospective cohort on university students’ health. Participants are registered in the first years of study initially with the Universities of Bordeaux and Versailles-Saint-Quentin many many other French universities are now participating. Students are followed up with yearly assessments.

The study sets 2 main types of objectives:

1. Evaluate the frequency and impact of several diseases that may have immediate or short-term consequences on health and well-being (e.g. stress and depression, migraine, sexually transmitted infectious diseases, etc.).
2. Biomedical research objectives on the determinants of diseases. We have set up a cerebral MRI study and biobank on a sample of about 2000 participants including DNA and RNA.

The longitudinal Study of Cognitive Change in Normal Healthy Old Age (LSCC) is a population study including 6,342 healthy residence of Greater Manchester and Newcastle-upon-Tyne aged from 42 to 92 in 1983. Two different batteries of cognitive tests were alternately administered biennially with additional questionnaires and Dna sample collection until 2003. The aims of the study were to:

• to determine sources of variations in rates of cognitive change between individuals
• to identify factors that slow or accelerate cognitive ageing and that prolong mental productivity or accelerate decline
• to generate and test functional models for the processes of biological ageing, especially of ageing of the brain and the central nervous system
• to test whether the neurophysiological and consequent cognitive changes differ in idiosyncratic patterns between individuals

The Maastricht Aging Study (MAAS) was designed to specify the usual and pathological aging of cognitive function. MAAS is devoted to the age-related decline of memory and other cognitive functions in normal people and the factors that may be involved in this process. What determines a decline in memory function? Why do some individuals show a greater decline than others? Over the past years, a host of factors, including biological, medical, psychological and social variables, have been proposed to have an impact on adult cognitive development. MAAS tries to study these factors in an integrative way. This can be achieved only by studying large numbers of normal healthy adults of all ages and by monitoring them for several years.

The LRRK2 Cohort Consortium (LCC) comprises three closed studies: the LRRK2 Cross-sectional Study, LRRK2 Longitudinal Study and the 23andMe Blood Collection Study. The LCC followed standardized data acquisition protocols, and clinical data and biological samples are stored in a comprehensive Parkinson’s database and biorepository, respectively. A total of 1,213 Idiopathic PD subjects, 1,168 PD subjects with genetic mutations in LRRK2, 1,123 unaffected subjects with genetic mutations in LRRK2, and 779 Healthy Controls (HC) were recruited.

The Parkinson’s Progression Marker Initiative (PPMI) is an observational, international study designed to establish biomarker defined cohorts and identify clinical, imaging, genetic and biospecimen Parkinson’s disease (PD) progression markers to accelerate disease modifying therapeutic trials. A total of 423 untreated PD, 196 Healthy Control (HC), 64 SWEDD (scans without evidence of dopaminergic deficit) subjects, and 65 Prodromal subjects (individuals with hyposmia or REM Sleep Behavior Disorder) were enrolled. PPMI is actively enrolling affected and unaffected individuals with genetic mutations in LRRK2, GBA, or SNCA through the end of 2018. For the most up to date enrollment numbers, please visit http://www.ppmi-info.org/study-design/study-cohorts/. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.